As in CML, LSC are in the CD34+ cell compartment, we could compare the in vitro uptake of nilotinib by mature CD34- (PMN) and immature (CD34+) cells from 30 patients with CML (Fig. 2B). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.